Cargando…

Therapeutic use of monoclonal antibodies: general aspects and challenges for drug delivery

Monoclonal antibodies are routinely used in several fields but the great challenge has been their use as therapeutic agents for the treatment of diseases, such as breast cancer, leukemia, asthma, macular degeneration, arthritis, Crohn’s disease, and transplants, among others. Monoclonal antibodies a...

Descripción completa

Detalles Bibliográficos
Autores principales: Quinteros, Daniela A., Bermúdez, José M., Ravetti, Soledad, Cid, Alicia, Allemandi, Daniel A., Palma, Santiago D.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7151974/
http://dx.doi.org/10.1016/B978-0-323-46143-6.00025-7
_version_ 1783521372805267456
author Quinteros, Daniela A.
Bermúdez, José M.
Ravetti, Soledad
Cid, Alicia
Allemandi, Daniel A.
Palma, Santiago D.
author_facet Quinteros, Daniela A.
Bermúdez, José M.
Ravetti, Soledad
Cid, Alicia
Allemandi, Daniel A.
Palma, Santiago D.
author_sort Quinteros, Daniela A.
collection PubMed
description Monoclonal antibodies are routinely used in several fields but the great challenge has been their use as therapeutic agents for the treatment of diseases, such as breast cancer, leukemia, asthma, macular degeneration, arthritis, Crohn’s disease, and transplants, among others. Monoclonal antibodies are protein molecules made in the laboratory from hybridoma cells by recombinant DNA technology. Important advances have been made over the past decade to improve some critical points, such as safety and efficacy of the first generation of therapeutic antibodies. This type of molecules presents a significant challenge from the pharmaceutical point of view due to their characteristics, such as molecular size, stability, and solubility. In this chapter we have attempted to identify the major issues associated with therapeutic approaches, formulating drawbacks and delivering antibody drugs, particularly focused on the challenges and opportunities that these present for the future.
format Online
Article
Text
id pubmed-7151974
institution National Center for Biotechnology Information
language English
publishDate 2017
record_format MEDLINE/PubMed
spelling pubmed-71519742020-04-13 Therapeutic use of monoclonal antibodies: general aspects and challenges for drug delivery Quinteros, Daniela A. Bermúdez, José M. Ravetti, Soledad Cid, Alicia Allemandi, Daniel A. Palma, Santiago D. Nanostructures for Drug Delivery Article Monoclonal antibodies are routinely used in several fields but the great challenge has been their use as therapeutic agents for the treatment of diseases, such as breast cancer, leukemia, asthma, macular degeneration, arthritis, Crohn’s disease, and transplants, among others. Monoclonal antibodies are protein molecules made in the laboratory from hybridoma cells by recombinant DNA technology. Important advances have been made over the past decade to improve some critical points, such as safety and efficacy of the first generation of therapeutic antibodies. This type of molecules presents a significant challenge from the pharmaceutical point of view due to their characteristics, such as molecular size, stability, and solubility. In this chapter we have attempted to identify the major issues associated with therapeutic approaches, formulating drawbacks and delivering antibody drugs, particularly focused on the challenges and opportunities that these present for the future. 2017 2017-03-31 /pmc/articles/PMC7151974/ http://dx.doi.org/10.1016/B978-0-323-46143-6.00025-7 Text en Copyright © 2017 Elsevier Inc. All rights reserved. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
spellingShingle Article
Quinteros, Daniela A.
Bermúdez, José M.
Ravetti, Soledad
Cid, Alicia
Allemandi, Daniel A.
Palma, Santiago D.
Therapeutic use of monoclonal antibodies: general aspects and challenges for drug delivery
title Therapeutic use of monoclonal antibodies: general aspects and challenges for drug delivery
title_full Therapeutic use of monoclonal antibodies: general aspects and challenges for drug delivery
title_fullStr Therapeutic use of monoclonal antibodies: general aspects and challenges for drug delivery
title_full_unstemmed Therapeutic use of monoclonal antibodies: general aspects and challenges for drug delivery
title_short Therapeutic use of monoclonal antibodies: general aspects and challenges for drug delivery
title_sort therapeutic use of monoclonal antibodies: general aspects and challenges for drug delivery
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7151974/
http://dx.doi.org/10.1016/B978-0-323-46143-6.00025-7
work_keys_str_mv AT quinterosdanielaa therapeuticuseofmonoclonalantibodiesgeneralaspectsandchallengesfordrugdelivery
AT bermudezjosem therapeuticuseofmonoclonalantibodiesgeneralaspectsandchallengesfordrugdelivery
AT ravettisoledad therapeuticuseofmonoclonalantibodiesgeneralaspectsandchallengesfordrugdelivery
AT cidalicia therapeuticuseofmonoclonalantibodiesgeneralaspectsandchallengesfordrugdelivery
AT allemandidaniela therapeuticuseofmonoclonalantibodiesgeneralaspectsandchallengesfordrugdelivery
AT palmasantiagod therapeuticuseofmonoclonalantibodiesgeneralaspectsandchallengesfordrugdelivery